PubAg

Main content area

Comparative inhibitory potential of selected dietary bioactive polyphenols, phytosterols on CYP3A4 and CYP2D6 with fluorometric high-throughput screening

Author:
Vijayakumar, Thangavel Mahalingam, Kumar, Ramasamy Mohan, Agrawal, Aruna, Dubey, Govind Prasad, Ilango, Kaliappan
Source:
Journal of food science and technology 2015 v.52 no.7 pp. 4537-4543
ISSN:
0022-1155
Subject:
beta-sitosterol, bioactive compounds, cytochrome P-450, dietary supplements, dimethyl sulfoxide, ellagic acid, fluorometry, food intake, gallic acid, herbal medicines, inhibitory concentration 50, liver, microsomes, polyphenols, quercetin, rats, rutin, screening, stigmasterol, toxicity
Abstract:
Cytochrome P450 (CYP450) inhibition by the bioactive molecules of dietary supplements or herbal products leading to greater potential for toxicity of co-administered drugs. The present study was aimed to compare the inhibitory potential of selected common dietary bioactive molecules (Gallic acid, Ellagic acid, β-Sitosterol, Stigmasterol, Quercetin and Rutin) on CYP3A4 and CYP2D6 to assess safety through its inhibitory potency and to predict interaction potential with co-administered drugs. CYP450-CO complex assay was carried out for all the selected dietary bioactive molecules in isolated rat microsomes. CYP450 concentration of the rat liver microsome was found to be 0.474 nmol/mg protein, quercetin in DMSO has shown maximum inhibition on CYP450 (51.02 ± 1.24 %) but less when compared with positive control (79.02 ± 1.61 %). In high throughput fluorometric assay, IC₅₀ value of quercetin (49.08 ± 1.02–54.36 ± 0.85 μg/ml) and gallic acid (78.46 ± 1.32–83.84 ± 1.06 μg/ml) was lower than other bioactive compounds on CYP3A4 and CYP2D6 respectively but it was higher than positive controls (06.28 ± 1.76–07.74 ± 1.32 μg/ml). In comparison of in vitro inhibitory potential on CYP3A4 and CYP2D6, consumption of food or herbal or dietary supplements containing quercetin and gallic acid without any limitation should be carefully considered when narrow therapeutic drugs are administered together.
Agid:
4406842